Antiretroviral toxicities – Ana Milinkovic Welcome to your Antiretroviral toxicities - Ana Milinkovic 1. When comparing tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF), TAF is associated with less bone and kidney toxicity whereas TDF is associated with lower lipid levels. a. True b. False 2. The prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) is higher in People living with HIV (PLWH). Options for treatment of NAFLD include:- a. Life style modification and weight reduction b. Consider change of antiretroviral therapy c. Consider investigational agents including CCR5 antagonists, tesamorelin d. Consider the use of statins e. All of the above 3. If a patient’s eGFR is 38 ml/min/1.73m2, and has both glycosuria and proteinuria, would you continue TAF? a. Yes b. No 4. Frailty is a clinical syndrome associated with ageing and is more prevalent in PLWH. Which of the below statement (s) are true? a. • Key indicators of frailty include – shrinking (weight loss), muscle weakness, poor endurance/exhaustion, slowness, and low activity b • Frailty is NOT associated with an increased risk of hospitalisation and shorter survival c. • Preventive measures such as exercise, smoking cessation, and avoidance of advance immunodeficiency are critical 5. British HIV Association guidance recommend assessment of fracture risk to be performed:- a. In everyone aged >50 years, post-menopausal women or other high risk individuals every 3 years b. In everyone aged > 50 years, post-menopausal women or other high risk individuals every 10 years Time is Up!